Venous thromboembolic disease: Clinical practice guidelines in oncology Journal Article

  


Authors: Streiff, M. B.; Bockenstedt, P. L.; Cataland, S. R.; Chesney, C.; Eby, C.; Fanikos, J.; Fogarty, P. F.; Gao, S.; Garcia-Aguilar, J.; Goldhaber, S. Z.; Hassoun, H.; Hendrie, P.; Holmstrom, B.; Jones, K. A.; Kuderer, N.; Lee, J. T.; Millenson, M. M.; Neff, A. T.; Ortel, T. L.; Smith, J. L.; Yee, G. C.; Zakarija, A.
Article Title: Venous thromboembolic disease: Clinical practice guidelines in oncology
Abstract: Recognizing the increased risk of VTE in cancer patients is the first step in preventing the occurrence of VTE and promptly identifying VTE in these patients. The panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who do not have contraindications to this therapy, and also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. After hospital discharge, the panel recommends that cancer patients in a high-risk setting for VTE (e.g., patients who have undergone cancer surgery, those with multiple myeloma) continue to receive VTE prophylaxis, with the duration of anticoagulation determined by the clinical situation. Careful evaluation of cancer patients in whom VTE is suspected, and prompt treatment and follow-up for those diagnosed with VTE, is recommended after the cancer status of the patient is assessed and the risks and benefits of treatment are considered. © JNCCN-Journal of the National Comprehensive Cancer Network.
Keywords: lenalidomide; thalidomide; review; bevacizumab; doxorubicin; side effect; treatment; unindexed drug; erythropoietin; bleeding; nccn clinical practice guidelines; dexamethasone; deep vein thrombosis; practice guideline; oncology; pulmonary embolism; hyponatremia; acetylsalicylic acid; prophylaxis; warfarin; heparin; tamoxifen; anticoagulation; anaphylaxis; oral contraceptive agent; myeloma; heparin induced thrombocytopenia; enoxaparin; fondaparinux; lepirudin; thrombocyte transfusion; paralysis; venous thromboembolism; argatroban; dalteparin; tinzaparin; raloxifene; vitamin k group; nccn guidelines; recombinant blood clotting factor 7a; epidural hematoma; hirulog; deep venous thrombosis; low-molecular-weight heparin; superficial vein thrombosis; aminocaproic acid; blood clotting factor 10a inhibitor; desmopressin; phytomenadione; protamine; prothrombin complex; thrombin inhibitor; tranexamic acid; blood clot lysis; spinal hematoma; tachyphylaxis
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 9
Issue: 7
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2011-07-01
Start Page: 714
End Page: 777
Language: English
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-79960092301&partnerID=40&md5=3fd7f7a26cc00626c663bb9c2d5617c0
Notes: --- - "Export Date: 17 August 2011" - "Source: Scopus"